WO1999004801A1 - Utilisation de glycosaminoglycanes sulfates dans le traitement de la retinopathie - Google Patents
Utilisation de glycosaminoglycanes sulfates dans le traitement de la retinopathie Download PDFInfo
- Publication number
- WO1999004801A1 WO1999004801A1 PCT/EP1998/004929 EP9804929W WO9904801A1 WO 1999004801 A1 WO1999004801 A1 WO 1999004801A1 EP 9804929 W EP9804929 W EP 9804929W WO 9904801 A1 WO9904801 A1 WO 9904801A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- retinopathy
- pharmaceutically acceptable
- treating
- sulfated glycosaminoglycan
- use according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
Definitions
- the invention relates to the use of sulfated glycosaminoglycans and/or synthetic functional analogues thereof for the manufacture of a medicament for treating and preventing of retinopathy. Further the invention relates to a pharmaceutical composition for said use.
- a severe disorder in diabetic retinopathy is so-called background retinopathy, which is caused by retinal leakage.
- Diabetes induces a deterioration of the condition of the basement membrane of the retinal capillary blood vessels resulting in increased permeability of the capillary blood vessels, which results, in turn, in increased leakage of proteins.
- This leads to swelling of the retina (oedema) and the formation of deposits of the proteins on the retina (hard exudates in diabetic maculopathy), which impaires the eyesight and may finally cause blindness.
- sulfated glycosaminoglycans and/or synthetic functional analogues thereof or pharmaceutically acceptable salts thereof can be used to treat and prevent retinopathy. This is in particular successful in diabetic background retinopathy, caused by increased permeability of capillary blood vessels on the retina.
- the use of the sulfated glycosaminoglycans and/or synthetic functional analogues thereof or pharmaceutically acceptable salts thereof according to this invention results in effective improvement of the condition of the retina of diabetes patients with background retinopathy. In particular the progression of hard exudates stops and is even reversed.
- the use of this invention can be the only therapy used to treat to a patient, but it may also be an adjuvans treatment together with other therapies, such as focal laser therapy.
- the class of sulfated glycosaminoglycans which can be used according to this invention comprises heparin, low molecular weight heparins (L W ⁇ s) like dalteparin (Fragmin®), enoxaparin (Clexane®) and nadroparin (Fraxiparine®), and especially sulfated glycosaminoglycans for the major part consisting of heparan sulfate, in particular those described in EP 421,508 (66 % to 95 % heparan sulfate), of which the commercially available danaparoid sodium (danaparoid; Orgaran®, N.V.
- the sulfated glycosaminoglycan and/or a synthetic functional analogue thereof or a pharmaceutically acceptable salt thereof may be administered enterally (e.g. orally or topically) or parenterally (e.g. via the subcutaneous or intravenous route).
- the active agent is administered as a subcutaneous injection to the mammal undergoing treatment.
- the mammal is a human.
- the dosage is 0,001-10 mg per kg body weight per treatment. More preferably, the active agent is administered at doses of between 1 mg and 150 mg, and most preferably between 30 mg and 100 mg, per patient per treatment.
- the active agent may be used alone or in combination with other therapeutic agents and may be presented as a pharmaceutical composition.
- the present invention further provides a pharmaceutical composition for treating and preventing of retinopathy comprising said active agent together with pharmaceutically acceptable auxiliaries and optionally other therapeutic agents.
- the term "acceptable" means being compatible with the other ingredients of the composition and not deleterious to the recipients thereof.
- Compositions include e.g. those suitable for oral, sublingual, subcutaneous, intravenous, intramuscular, transdermal, transmucosal, local, or rectal administration, and the like, all in unit dosage forms for administration.
- the active ingredient may be presented as discrete units, such as tablets, capsules, powders, granulates, solutions, suspensions, and the like.
- the pharmaceutical composition of the invention may be presented in unit-dose or multi-dose containers, e.g. injection liquids in predetermined amounts, for example in sealed vials and ampoules, and may also be stored in a freeze dried (lyophilized) condition requiring only the addition of sterile liquid carrier, e.g. water, prior to use.
- sterile liquid carrier e.g. water
- the active agent may be compressed into solid dosage units, such as pills, tablets, or be processed into capsules or suppositories.
- the active agent can be applied as a fluid composition, e.g. as an injection preparation, in the form of a solution, suspension, emulsion, or as a spray, e.g. a nasal spray.
- solid dosage units For making solid dosage units, the use of conventional additives such as fillers, colorants, polymeric binders and the like is contemplated. In general any pharmaceutically acceptable additive which does not interfere with the function of the active compounds can be used. Suitable carriers with which the active agent of the invention can be administered as solid compositions include lactose, starch, cellulose derivatives and the like, or mixtures thereof, used in suitable amounts. For parenteral administration, aqueous suspensions, isotone saline solutions and sterile injectable solutions may be used, containing pharmaceutically acceptable dispersing agents and/or wetting agents, such as propylene glycol or butylene glycol.
- the invention further includes a pharmaceutical composition, as hereinbefore described, in combination with packaging material suitable for said composition, said packaging material including instructions for the use of the composition for the use as hereinbefore described.
- a pharmaceutical composition as hereinbefore described, in combination with packaging material suitable for said composition, said packaging material including instructions for the use of the composition for the use as hereinbefore described.
- Danaparoid sodium as a representative compound for use according to the present invention, has been subject to a pilot clinical study in 9 patients with diabetes mellitus.
- Danaparoid sodium is a mixture of sulfated glycosaminoglycans, consisting of 84% heparan sulfate, 12% dermatan sulfate and 4% chondroitin sulfate isolated from digested porcine intestinal mucosa. It has an average molecular weight of 4000-7000 d, and a specific anti-Xa activity of 1 1.0-17.0 U/mg. The elimination half-life of anti-Xa activity is ⁇ 25 h.
- danaparoid sodium formulation used is a sterile aqueous solution containing danaparoid sodium (1250 anti Xa units per ml), sodium sulfite (1.5 mg/ml), sodium chloride to isotonic and hydrochloric acid to pH 7.0. In this study 0.6 ml ampoules were used.
- the study was designed as a phase II, randomized, double blind, placebo controlled, crossover study evaluating putative effects of danaparoid sodium on the rate of proteinuria in insulin dependent diabetic mellitus (IDDM) patients (J.Am.Soc.Nephrol. 8, 456-62, 1997).
- IDDM insulin dependent diabetic mellitus
- IQR interquartile range
- Mean arterial blood pressure was 105 mrnHg (median) (IQR 100-107); the use of angiotensin I converting enzyme inhibitors and other anti hypertensive medications was on a stable dosage at least 6 weeks prior to the start of the study and remained unchanged. Median HbAlc was 8.3% (IQR 7.7-9.8%). Six out of 9 patients had undergone pattern photocoagulation previously because of proliferative retinopathy. The other 3 patients had stable background retinopathy. At baseline, in 7 patients hard exudates were present in both eyes.
- the patients were randomly assigned to one of the treatment orders: 750 anti-Xa units danaparoid sodium (0.6 ml), subcutaneously administered once daily for 6 weeks; a wash-out period of 4 weeks, followed by 6 weeks placebo (saline with sulfite) or the same scheme in the opposite direction.
- Fundus photography was performed at inclusion and at the end of the study. Seven field, red- free photographs of both eyes were obtained after mydriasis with a Zeiss camera. No bleeding complications were observed.
- To evaluate the course of signs of retinal leakage a 45° photograph centered around the fovea was projected and all hard exudates were traced. Photographs were studied anonymous, masked for pre- or post-treatment assessment. Hard exudates were semi-quantitatively graded, ranging from 1+ (only minimal) to 5+ (extensive circinate).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne l'utilisation d'un glycosaminoglycane sulfaté et/ou de son analogue synthétique fonctionnel ou de son sel pharmaceutiquement acceptable dans la fabrication d'un médicament destiné au traitement ou à la prévention de la rétinopathie diabétique de fond.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU91604/98A AU9160498A (en) | 1997-07-28 | 1998-07-23 | Use of sulfated glycosaminoglycans for treating of retinopathy |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97202362 | 1997-07-28 | ||
NL97202362.6 | 1997-07-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999004801A1 true WO1999004801A1 (fr) | 1999-02-04 |
Family
ID=8228599
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1998/004929 WO1999004801A1 (fr) | 1997-07-28 | 1998-07-23 | Utilisation de glycosaminoglycanes sulfates dans le traitement de la retinopathie |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU9160498A (fr) |
WO (1) | WO1999004801A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999021538A2 (fr) * | 1997-10-24 | 1999-05-06 | Knoll Aktiengesellschaft | Utilisation de glycosaminoglycanes pour la fabrication de preparations pharmaceutiques en vue du traitement de maladies des yeux associees au diabete |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0244298A2 (fr) * | 1986-04-17 | 1987-11-04 | Sanofi | Oligosaccharides hépariniques affinés pour les facteurs de croissance cellulaires |
WO1990000058A1 (fr) * | 1988-06-27 | 1990-01-11 | Roland Reiner | Glycosaminoglycane pour le traitement de la microangiopathie des diabetiques |
EP0394971A1 (fr) * | 1989-04-24 | 1990-10-31 | Kabi Pharmacia Ab | Inhibiteurs de croissance de cellules endothéoliales et d'angiogénèse contenant un oligosaccharide |
WO1995005182A1 (fr) * | 1993-08-13 | 1995-02-23 | Glycomed Incorporated | Oligosaccharides pontes et leurs derives sulfates |
WO1996009828A1 (fr) * | 1994-09-26 | 1996-04-04 | Glycomed Incorporated | Maltooligosaccharides fortement sulfates presentant des proprietes analogues a celles de l'heparine |
-
1998
- 1998-07-23 WO PCT/EP1998/004929 patent/WO1999004801A1/fr active Application Filing
- 1998-07-23 AU AU91604/98A patent/AU9160498A/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0244298A2 (fr) * | 1986-04-17 | 1987-11-04 | Sanofi | Oligosaccharides hépariniques affinés pour les facteurs de croissance cellulaires |
WO1990000058A1 (fr) * | 1988-06-27 | 1990-01-11 | Roland Reiner | Glycosaminoglycane pour le traitement de la microangiopathie des diabetiques |
EP0394971A1 (fr) * | 1989-04-24 | 1990-10-31 | Kabi Pharmacia Ab | Inhibiteurs de croissance de cellules endothéoliales et d'angiogénèse contenant un oligosaccharide |
WO1995005182A1 (fr) * | 1993-08-13 | 1995-02-23 | Glycomed Incorporated | Oligosaccharides pontes et leurs derives sulfates |
WO1996009828A1 (fr) * | 1994-09-26 | 1996-04-04 | Glycomed Incorporated | Maltooligosaccharides fortement sulfates presentant des proprietes analogues a celles de l'heparine |
Non-Patent Citations (2)
Title |
---|
AIELLO L P ET AL: "VASCULAR ENDOTHELIAL GROWTH FACTOR IN OCULAR FLUID OF PATIENTS WITH DIABETIC RETINOPATHY AND OTHER RETINA DISORDERS", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 331, no. 22, 1 December 1994 (1994-12-01), pages 1480 - 1487, XP000574787 * |
CHEMICAL ABSTRACTS, vol. 124, no. 3, 15 January 1996, Columbus, Ohio, US; abstract no. 26667b, FAVARD ET AL.: "Heparin-binding growth factors: FGF and VEGF. Physiological and pathological roles, and therapeutic implications in diabetic retinopathy." page 663; XP002054088 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999021538A2 (fr) * | 1997-10-24 | 1999-05-06 | Knoll Aktiengesellschaft | Utilisation de glycosaminoglycanes pour la fabrication de preparations pharmaceutiques en vue du traitement de maladies des yeux associees au diabete |
WO1999021538A3 (fr) * | 1997-10-24 | 1999-08-05 | Knoll Ag | Utilisation de glycosaminoglycanes pour la fabrication de preparations pharmaceutiques en vue du traitement de maladies des yeux associees au diabete |
Also Published As
Publication number | Publication date |
---|---|
AU9160498A (en) | 1999-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0706398B1 (fr) | Composition pharmaceutique contenant de l'heparine, des fragments d'heparine ou leurs derives, combines avec des esters de glycerol | |
EP1192947B1 (fr) | Composition pharmaceutique pour usage ophthalmique comprenant du trehalose | |
EP0235544B1 (fr) | Composition oculaire antihypertensive pour l'utilisation topique | |
JP2010513366A (ja) | 眼科用薬物の輸送に有用なゲル | |
JPH06329541A (ja) | 糖尿病性腎症治療用スロデキサイド含有医薬 | |
AU701014B2 (en) | Treatment of disease and conditions associated with macrophage infiltration in particular stroke and myocardial infarction | |
JPS62126125A (ja) | 糖尿病性合併症治療薬 | |
JP2967523B2 (ja) | 眼病用製薬組成物 | |
US7354910B2 (en) | Agent for treating inflammatory bowel diseases | |
JPH0352815A (ja) | 血管内血液凝固症候群の治療剤 | |
KR100342367B1 (ko) | 녹내장치료제및안압강하제 | |
WO1999004801A1 (fr) | Utilisation de glycosaminoglycanes sulfates dans le traitement de la retinopathie | |
AU714086B2 (en) | Use of COMT inhibitors for the manufacture of a medicament for the prevention of diabetic vascular dysfunctions | |
EP0647445B1 (fr) | Composition pour la prévention et le traitement de la myopie | |
US5352702A (en) | Method for treating glaucoma | |
AU749673B2 (en) | Use of glycosaminoglycans for producing pharmaceutical preparations for treating diabetes-associated diseases of the eye | |
JPS63502270A (ja) | 散瞳作用を有する眼科用医薬組成物 | |
CA2005754A1 (fr) | Combinaisons d'enzyme convertisseur de l'angiotensine et d'anhydrase carbonique comme inhibiteurs pour le traitement du glaucome | |
STEWART | Review timolol hemihydrate: A new formulation of Timolol for the treatment of glaucoma | |
EP0406210B1 (fr) | Composition ophtalmique | |
JPH1036255A (ja) | 眼圧降下用点眼剤 | |
US5733938A (en) | Combination of levobunolol and dipivefrin for topical ophthalmic use | |
CA2476908A1 (fr) | Utilisation d'un sel d'acide l-ascorbique pour preparer une composition pharmaceutique pour une utilisation topique ophtalmique capable d'ameliorer le niveau d'acide l-ascorbique dans l'oeil | |
WO1995033456A2 (fr) | Reduction de la pression intraoculaire au moyen d'acide aryloxyacetique et d'acide arylacetique | |
JPH1025252A (ja) | 補体依存性疾患治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AU BA BB BG BR CA CN CU CZ EE GE HU ID IL IS JP KP KR LC LK LR LT LV MG MK MN MW MX NO NZ PL RO RU SD SG SI SK SL TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: KR |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
122 | Ep: pct application non-entry in european phase |